Blue Trust Inc. Acquires 8,208 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Blue Trust Inc. grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 134.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,302 shares of the biotechnology company’s stock after buying an additional 8,208 shares during the period. Blue Trust Inc.’s holdings in Exelixis were worth $476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of EXEL. FMR LLC lifted its stake in Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after purchasing an additional 140,568 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Exelixis by 6.1% in the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock worth $44,182,000 after buying an additional 98,000 shares in the last quarter. Systematic Financial Management LP boosted its stake in Exelixis by 7.1% during the third quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock valued at $30,320,000 after buying an additional 77,599 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in Exelixis by 24.6% during the 3rd quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock valued at $23,653,000 after buying an additional 180,021 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of EXEL stock opened at $33.15 on Friday. The company’s 50-day simple moving average is $34.68 and its two-hundred day simple moving average is $30.08. Exelixis, Inc. has a one year low of $20.01 and a one year high of $37.59. The company has a market capitalization of $9.47 billion, a P/E ratio of 21.25, a P/E/G ratio of 0.72 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period last year, the business posted $0.10 EPS. Exelixis’s quarterly revenue was up 14.3% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on EXEL. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Truist Financial increased their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. Finally, Guggenheim restated a “buy” rating on shares of Exelixis in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $36.06.

Insider Transactions at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the transaction, the executive vice president now owns 288,665 shares in the company, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 208,574 shares of company stock valued at $7,376,374. 2.85% of the stock is currently owned by corporate insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.